Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rational design of switchable aptamer sensors through structural and thermodynamic tuning.

Chemical communications (Cambridge, England)·2026

Same author

Comparative Analysis of Selected UGT and SULT mRNA Expression in Non-Obese Rat Models of Metabolic Syndrome.

Biomedicines·2026

Same author

In Vitro Cytochrome P450 Interaction Profile and ADME Characterisation of Gold(I)-Triphenylphosphine Complexes with 6-Alkoxy-9-deazapurine Ligands.

Pharmaceutics·2026

Same author

Eutectic Processing of Semiconductor Colloidal Nanocrystals for Energy Applications.

ACS energy letters·2026

Same author

Pyrrole-Imine Macrocycle: Self-Organizing Cross-Reactive Anion Receptor and Sensor.

Chemistry (Weinheim an der Bergstrasse, Germany)·2025

Same author

Overcoming the Hydration and Solvation Problem in Ion Recognition and Binding: The Biomimetic Approach.

Accounts of chemical research·2025

Search research articles

Related Experiment Video

Updated: May 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat.

Rostislav Večeřa¹, Alice Zachařová, Jan Orolin

¹Institute of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská, 3, 775 15 Olomouc, Czech Republic.

Biopharmaceutics & Drug Disposition

|October 5, 2011

Summary

Fenofibrate, a lipid-lowering drug, significantly suppresses rat CYP2C11 and CYP2C6 enzymes. This interaction with fenofibrate may potentiate the effects of drugs like warfarin metabolized by human CYP2C9.

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

Pharmacology
Drug Metabolism
Biochemistry

Background:

Cytochrome P450 enzymes, specifically CYP2C9 in humans, metabolize crucial drugs like warfarin and NSAIDs.
Fenofibrate is a widely prescribed hypolipidemic agent.
Rat CYP2C11 and CYP2C6 are functional counterparts of human CYP2C9.

Purpose of the Study:

To investigate the impact of fenofibrate on rat CYP2C11 and CYP2C6 enzyme expression.
To explore potential drug interactions between fenofibrate and CYP2C9-metabolized drugs.

Main Methods:

Administration of fenofibrate (0.1% w/w) in diet to Wistar and hypertriglyceridemic rats for 20 days.
Quantification of CYP2C11 and CYP2C6 mRNA and protein levels in liver microsomes.

Main Results:

Fenofibrate significantly suppressed CYP2C11 mRNA and protein expression in both rat strains.
A less pronounced but significant suppression of CYP2C6 mRNA and protein was observed.
These effects were consistent across healthy and hypertriglyceridemic rat models.

Conclusions:

Fenofibrate significantly downregulates rat CYP2C11 and CYP2C6, analogous to human CYP2C9.
Caution is advised when co-administering fenofibrate with CYP2C9 substrates (e.g., warfarin) due to potential potentiation of effects.
This study provides mechanistic insights into fenofibrate-drug interactions.